The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial
Open accessAbstract
BACKGROUND: Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, has shown superior efficacy to etanercept with similar safety in moderate to severe plaque psoriasis (FIXTURE study). OBJECTIVE: We sought to directly compare efficacy and safety of secukinumab versus ustekinumab. METHODS: In this 52-week, double-blind study (NCT02074982), 676 subjects were randomized 1:1 to subcutaneous injection of secukinumab 300 mg or ustekinumab per label. Primary end point was 90% or more improvement from baseline Psoriasis Area and Severity Index (PASI) score (PASI 90) at week 16. RESULTS: Secukinumab (79.0%) was superior to ustekinumab (57.6%) as assessed by PASI 90 response at week 16 (P < .0001). The 100% improvement from baseline PASI score at week 16 was also significantly greater with secukinumab (44.3%) than ustekinumab (28.4%) (P < .0001). The 75% or more improvement from baseline PASI score at week 4 was superior for secukinumab (50.0%) versus ustekinumab (20.6%) (P < .0001). Percentage of subjects with the Dermatology Life Quality Index score 0/1 (week 16) was significantly higher with secukinumab (71.9%) than ustekinumab (57.4%) (P < .0001). The safety profile of secukinumab was comparable with ustekinumab and consistent with pivotal phase III secukinumab studies. LIMITATIONS: The study was not placebo-controlled and of short-term duration. CONCLUSIONS: Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe psoriasis and improving health-related quality of life with a comparable safety profile over 16 weeks.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use
FINLAY, A. Y., & KHAN, G. K. (1994) · Clinical and Experimental Dermatology · doi:10.1111/j.1365-2230.1994.tb01167.x · Cited by 5,586
Nestle, F. O., Kaplan, D. H., & Barker, J. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0804595 · Cited by 2,786
Secukinumab in plaque psoriasis—results of two phase 3 trials
Langley, R. G., Elewski, B. E., Lebwohl, M., Reich, K., Griffiths, C. E. M., Papp, K., Puig, L., Nakagawa, H., Spelman, L., Sigurgeirsson, B., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1314258 · Cited by 1,997
Leonardi, C. L., Kimball, A. B., Papp, K. A., Yeilding, N., Guzzo, C., Wang, Y., Li, S., Dooley, L. T., & Gordon, K. B. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60725-4 · Cited by 1,874
Papp, K. A., Langley, R. G., Lebwohl, M., Krueger, G. G., Szapary, P., Yeilding, N., Guzzo, C., Hsu, M.-C., Wang, Y., Li, S., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60726-6 · Cited by 1,361
Self-citationEtanercept as Monotherapy in Patients with Psoriasis
Leonardi, C. L., Powers, J. L., Matheson, R. T., Goffe, B. S., Zitnik, R., Wang, A., & Gottlieb, A. B. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030409 · Cited by 1,175
Reich, K., Nestle, F. O., Papp, K., Ortonne, J.-P., Evans, R., Guzzo, C., Li, S., Dooley, L. T., & Griffiths, C. E. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67566-6 · Cited by 1,045
Self-citationAdalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial
Menter, A., Tyring, S. K., Gordon, K., Kimball, A. B., Leonardi, C. L., Langley, R. G., Strober, B. E., Kaul, M., Gu, Y., Okun, M., et al. (2008) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2007.09.010 · Cited by 889
Hueber, W., Patel, D. D., Dryja, T., Wright, A. M., Koroleva, I., Bruin, G., Antoni, C., Draelos, Z., Gold, M. H., the Psoriasis Study Group, et al. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3001107 · Cited by 860
Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis
Griffiths, C. E. M., Strober, B. E., van de Kerkhof, P., Ho, V., Fidelus-Gort, R., Yeilding, N., Guzzo, C., Xia, Y., Zhou, B., Li, S., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0810652 · Cited by 859
Cited by
Psoriasis Pathogenesis and Treatment
Rendon, A., & Schäkel, K. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20061475 · Cited by 2,064
Psoriasis pathogenesis and the development of novel targeted immune therapies
Hawkes, J. E., Chan, T. C., & Krueger, J. G. (2017) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2017.07.004 · Cited by 972
Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics
Menter, A., Strober, B. E., Kaplan, D. H., Kivelevitch, D., Prater, E. F., Stoff, B., Armstrong, A. W., Connor, C., Cordoro, K. M., Davis, D. M. R., et al. (2019) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2018.11.057 · Cited by 969
Greb, J. E., Goldminz, A. M., Elder, J. T., Lebwohl, M. G., Gladman, D. D., Wu, J. J., Mehta, N. N., Finlay, A. Y., & Gottlieb, A. B. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.82 · Cited by 922
Alinaghi, F., Calov, M., Kristensen, L. E., Gladman, D. D., Coates, L. C., Jullien, D., Gottlieb, A. B., Gisondi, P., Wu, J. J., Thyssen, J. P., et al. (2019) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2018.06.027 · Cited by 673
Singh, J. A., Guyatt, G., Ogdie, A., Gladman, D. D., Deal, C., Deodhar, A., Dubreuil, M., Dunham, J., Husni, M. E., Kenny, S., et al. (2019) · Arthritis & Rheumatology · doi:10.1002/art.40726 · Cited by 493
Th17 Cell Pathway in Human Immunity: Lessons from Genetics and Therapeutic Interventions
Patel, D. D., & Kuchroo, V. K. (2015) · Immunity · doi:10.1016/j.immuni.2015.12.003 · Cited by 486
Singh, J. A., Guyatt, G., Ogdie, A., Gladman, D. D., Deal, C., Deodhar, A., Dubreuil, M., Dunham, J., Husni, M. E., Kenny, S., et al. (2019) · Arthritis Care & Research · doi:10.1002/acr.23789 · Cited by 466
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis
Sbidian, E., Chaimani, A., Garcia-Doval, I., Do, G., Hua, C., Mazaud, C., Droitcourt, C., Hughes, C., Ingram, J. R., Naldi, L., et al. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011535.pub2 · Cited by 433
Bimekizumab versus Secukinumab in Plaque Psoriasis
Reich, K., Warren, R. B., Lebwohl, M., Gooderham, M., Strober, B., Langley, R. G., Paul, C., De Cuyper, D., Vanvoorden, V., Madden, C., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2102383 · Cited by 424
Self-citationIL-17 in Chronic Inflammation: From Discovery to Targeting
Beringer, A., Noack, M., & Miossec, P. (2016) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2016.01.001 · Cited by 402
Psoriatic arthritis: state of the art review
Coates, L. C., & Helliwell, P. S. (2017) · Clinical Medicine · doi:10.7861/clinmedicine.17-1-65 · Cited by 353
Reich, K., Papp, K. A., Blauvelt, A., Langley, R. G., Armstrong, A., Warren, R. B., Gordon, K. B., Merola, J. F., Okubo, Y., Madden, C., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00125-2 · Cited by 315
Self-citationBlauvelt, A., Reich, K., Tsai, T.-F., Tyring, S., Vanaclocha, F., Kingo, K., Ziv, M., Pinter, A., Vender, R., Hugot, S., et al. (2017) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2016.08.008 · Cited by 312
Self-citationComparison of Biologics and Oral Treatments for Plaque Psoriasis: A Meta-analysis
Armstrong, A. W., Puig, L., Joshi, A., Skup, M., Williams, D., Li, J., Betts, K. A., & Augustin, M. (2020) · JAMA Dermatology · doi:10.1001/jamadermatol.2019.4029 · Cited by 294
Deodhar, A., Mease, P. J., McInnes, I. B., Baraliakos, X., Reich, K., Blauvelt, A., Leonardi, C., Porter, B., Das Gupta, A., Widmer, A., et al. (2019) · Arthritis Research & Therapy · doi:10.1186/s13075-019-1882-2 · Cited by 292
Self-citationEgeberg, A., Ottosen, M. B., Gniadecki, R., Broesby-Olsen, S., Dam, T. N., Bryld, L. E., Rasmussen, M. K., & Skov, L. (2018) · British Journal of Dermatology · doi:10.1111/bjd.16102 · Cited by 284
McInnes, I. B., Behrens, F., Mease, P. J., Kavanaugh, A., Ritchlin, C., Nash, P., Masmitja, J. G., Goupille, P., Korotaeva, T., Gottlieb, A. B., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30564-x · Cited by 279
Saunte, D. M., Mrowietz, U., Puig, L., & Zachariae, C. (2017) · British Journal of Dermatology · doi:10.1111/bjd.15015 · Cited by 270
Fujita, H., Terui, T., Hayama, K., Akiyama, M., Ikeda, S., Mabuchi, T., Ozawa, A., Kanekura, T., Kurosawa, M., Komine, M., et al. (2018) · The Journal of Dermatology · doi:10.1111/1346-8138.14523 · Cited by 254
McGonagle, D. G., McInnes, I. B., Kirkham, B. W., Sherlock, J., & Moots, R. (2019) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2019-215356 · Cited by 254
Data extraction for evidence synthesis using a large language model: A proof-of-concept study
Gartlehner, G., Kahwati, L., Hilscher, R., Thomas, I., Kugley, S., Crotty, K., Viswanathan, M., Nussbaumer‐Streit, B., Booth, G., Erskine, N., et al. (2024) · Research Synthesis Methods · doi:10.1002/jrsm.1710 · Cited by 164
“In the study by Thaçi et al., 29 a standard deviation of the mean age of one treatment group was rounded incorrectly (should have been rounded to 14.0 not 13.9).”
InfluentialPerformance of two large language models for data extraction in evidence synthesis
Konet, A., Thomas, I., Gartlehner, G., Kahwati, L., Hilscher, R., Kugley, S., Crotty, K., Viswanathan, M., & Chew, R. (2024) · Research Synthesis Methods · doi:10.1002/jrsm.1732 · Cited by 79
Andrzejczak, K., Sternak, A., Witkowski, W., & Ponikowska, M. (2025) · Cells · doi:10.3390/cells14181442 · Cited by 10
“Compared to other biologics, such as ustekinumab and etanercept, secukinumab, with a comparable safety profile, provides better reduction in disease symptoms and greater improvement in quality of life [141].”
Metadata
- Authors
- Thaçi, D., Blauvelt, A., Reich, K., Tsai, T.-F., Vanaclocha, F., Kingo, K., Ziv, M., Pinter, A., Hugot, S., You, R., & Milutinovic, M.
- Venue
- Journal of the American Academy of Dermatology
- Publisher
- Elsevier BV
- Published
- 2015-09
- Volume
- 73
- Issue
- 3
- Pages
- 400-409
- ISSN
- 0190-9622 (ISSN-L)
- OpenAlex
- W1957267795
- Cited by
- 551
- References
- 25
- FWCI
- 30.50
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.